Please use this identifier to cite or link to this item:
|Title:||The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type|
Bode, Sebastian F. N.
Gahl, William A.
Gochuico, Bernadette R.
Mumford, Andrew D.
Saint Basile, Genevieve de
Karasu, Gulsun T.
Stadt, Udo zur
G proteins -- Recpetors -- Research -- Methodology
Flow cytometry -- Diagnostic use
Signal transducing adaptor proteins
|Publisher:||The American Society of Hematology|
|Citation:||Jessen, B., Bode, S. F., Ammann, S., Chakravorty, S., Davies, G., Diestelhorst, J., ... & Griffiths, G. (2013). The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood, 121(15), 2943-2951.|
|Abstract:||Genetic disorders of lymphocyte cytotoxicity predispose patients to hemophagocytic lymphohistiocytosis (HLH). Reduced lymphocyte cytotoxicity has been demonstrated in Hermansky-Pudlak syndrome type 2 (HPS2), but only a single patient was reported who developed HLH. Because that patient also carried a potentially contributing heterozygous RAB27A mutation, the risk for HLH in HPS2 remains unclear. We analyzed susceptibility to HLH in the pearl mouse model of HPS2. After infection with lymphocytic choriomeningitis virus, pearl mice developed all key features of HLH, linked to impaired virus control caused by a moderate defect in CTL cytotoxicity in vivo. However, in contrast to perforin-deficient mice, the disease was transient, and all mice fully recovered and controlled the infection. An additional heterozygous Rab27a mutation did not aggravate the cytotoxicity defect or disease parameters. In the largest survey of 22 HPS2 patients covering 234 patient years, we identified only 1 additional patient with HLH and 2 with incomplete transient HLH-like episodes, although cytotoxicity or degranulation was impaired in all 16 patients tested. HPS2 confers a risk for HLH that is lower than in Griscelli or Chediak-Higashi syndrome, probably because of a milder defect in cytotoxicity. Preemptive hematopoietic stem cell transplantation does not appear justified in HPS2. (Blood. 2013;121(15):2943-2951)|
|Appears in Collections:||Scholarly Works - FacM&SPae|
Files in This Item:
|The_risk_of_hemophagocytic_lymphohistiocytosis_in_Hermansky_Pudlak_syndrome_type.pdf||1.62 MB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.